Inovio Pharmaceuticals Inc vs Teradata Corporation Common Stock — how do they compare? Inovio Pharmaceuticals Inc trades at $0.99 (market cap $103.19M), while Teradata Corporation Common Stock trades at $29.6 (market cap $2.83B). The key difference: Teradata Corporation Common Stock is far larger — about 27.4× Inovio Pharmaceuticals Inc's market cap, and Teradata Corporation Common Stock is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Teradata Corporation Common Stock for 0 Days on average.
| INO | TDC | |
|---|---|---|
Market Cap | $103.19M | $2.83B |
Volume | 8,461,580 | 1,343,944 |
Sector | Health | Technology |
52-Week High | $2.60 | $37.88 |
52-Week Low | $0.66 | $20.71 |
Typical Hold Time | 43 Days | 0 Days |
Enterprise Value | $74.52M | $2.52B |
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals (INO) trades at $0.986, down 10.77% in the last session, with a bearish technical signal from moving averages. The company shows consistent quarterly earnings beats but operates with minimal revenue ($65K in 2025) and significant losses (-$85M net income). Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis. Analyst consensus remains positive with a $2.75 price target despite negative profitability metrics.
The stock presents high-risk biotech speculation with potential upside dependent on FDA approval. Current valuation metrics (P/S 961.51) reflect speculative optimism rather than fundamentals. Major risks include cash burn (-$21.5M net cash flow), regulatory uncertainty, and competitive pressures. Successful commercialization of INO-3107 is critical for viability.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →Teradata Corporation develops a hybrid cloud analytics and data platform, including its Teradata Vantage and VantageCloud products, that helps enterprises manage and analyze data across cloud, on-premises, and hybrid environments. It serves industries including retail, financial services, healthcare, and manufacturing.
Read more on TDC →